vs
Side-by-side financial comparison of GLACIER BANCORP, INC. (GBCI) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
GLACIER BANCORP, INC. is the larger business by last-quarter revenue ($306.8M vs $177.4M, roughly 1.7× Pacira BioSciences, Inc.). GLACIER BANCORP, INC. runs the higher net margin — 26.8% vs 1.6%, a 25.1% gap on every dollar of revenue. Over the past eight quarters, GLACIER BANCORP, INC.'s revenue compounded faster (24.3% CAGR vs -0.2%).
Glacier Bancorp, Inc. is a regional multi-bank holding company headquartered in Kalispell, Montana, United States. It is a successor corporation to the Delaware corporation originally incorporated in 1990. The company provides personal and commercial banking services from 221 locations in Montana, Idaho, Utah, Washington, Wyoming, Colorado, Arizona, and, Nevada.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
GBCI vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $306.8M | $177.4M |
| Net Profit | $82.1M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 26.8% | 1.6% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.63 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $306.8M | $177.4M | ||
| Q4 25 | $306.5M | $196.9M | ||
| Q3 25 | $260.7M | $179.5M | ||
| Q2 25 | $240.6M | $181.1M | ||
| Q1 25 | $222.6M | $168.9M | ||
| Q4 24 | $223.0M | $187.3M | ||
| Q3 24 | $214.9M | $168.6M | ||
| Q2 24 | $198.7M | $178.0M |
| Q1 26 | $82.1M | $2.9M | ||
| Q4 25 | $63.8M | — | ||
| Q3 25 | $67.9M | $5.4M | ||
| Q2 25 | $52.8M | $-4.8M | ||
| Q1 25 | $54.6M | $4.8M | ||
| Q4 24 | $61.8M | — | ||
| Q3 24 | $51.1M | $-143.5M | ||
| Q2 24 | $44.7M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 24.9% | 1.2% | ||
| Q3 25 | 32.7% | 3.5% | ||
| Q2 25 | 27.1% | 4.7% | ||
| Q1 25 | 28.5% | 1.2% | ||
| Q4 24 | 33.0% | 13.2% | ||
| Q3 24 | 28.9% | -82.8% | ||
| Q2 24 | 27.3% | 15.9% |
| Q1 26 | 26.8% | 1.6% | ||
| Q4 25 | 20.8% | — | ||
| Q3 25 | 26.0% | 3.0% | ||
| Q2 25 | 21.9% | -2.7% | ||
| Q1 25 | 24.5% | 2.8% | ||
| Q4 24 | 27.7% | — | ||
| Q3 24 | 23.8% | -85.1% | ||
| Q2 24 | 22.5% | 10.6% |
| Q1 26 | $0.63 | $0.07 | ||
| Q4 25 | $0.49 | $0.05 | ||
| Q3 25 | $0.57 | $0.12 | ||
| Q2 25 | $0.45 | $-0.11 | ||
| Q1 25 | $0.48 | $0.10 | ||
| Q4 24 | $0.55 | $0.38 | ||
| Q3 24 | $0.45 | $-3.11 | ||
| Q2 24 | $0.39 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2B | $653.9M |
| Total Assets | $31.7B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.4B | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $4.2B | $653.9M | ||
| Q4 25 | $4.2B | $693.1M | ||
| Q3 25 | $3.6B | $727.2M | ||
| Q2 25 | $3.5B | $757.8M | ||
| Q1 25 | $3.3B | $798.5M | ||
| Q4 24 | $3.2B | $778.3M | ||
| Q3 24 | $3.2B | $749.6M | ||
| Q2 24 | $3.1B | $879.3M |
| Q1 26 | $31.7B | $1.2B | ||
| Q4 25 | $32.0B | $1.3B | ||
| Q3 25 | $29.0B | $1.3B | ||
| Q2 25 | $29.0B | $1.5B | ||
| Q1 25 | $27.9B | $1.6B | ||
| Q4 24 | $27.9B | $1.6B | ||
| Q3 24 | $28.2B | $1.5B | ||
| Q2 24 | $27.8B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GBCI
| Net Interest Income | $268.7M | 88% |
| Noninterest Income | $38.1M | 12% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
